Attached files
| file | filename |
|---|---|
| EX-10.13 - EX-10.13 - Angion Biomedica Corp. | a2242860zex-10_13.htm |
| EX-10.7 - EX-10.7 - Angion Biomedica Corp. | a2242860zex-10_7.htm |
| EX-10.6(D) - EX-10.6(D) - Angion Biomedica Corp. | a2242860zex-10_6d.htm |
| EX-10.6(C) - EX-10.6(C) - Angion Biomedica Corp. | a2242860zex-10_6c.htm |
| EX-10.6(B) - EX-10.6(B) - Angion Biomedica Corp. | a2242860zex-10_6b.htm |
| EX-10.6(A) - EX-10.6(A) - Angion Biomedica Corp. | a2242860zex-10_6a.htm |
| EX-5.1 - EX-5.1 - Angion Biomedica Corp. | a2242860zex-5_1.htm |
| EX-4.2 - EX-4.2 - Angion Biomedica Corp. | a2242860zex-4_2.htm |
| EX-3.2 - EX-3.2 - Angion Biomedica Corp. | a2242860zex-3_2.htm |
| EX-1.1 - EX-1.1 - Angion Biomedica Corp. | a2242860zex-1_1.htm |
| S-1/A - S-1/A - Angion Biomedica Corp. | a2242860zs-1a.htm |
Consent of Independent Registered Public Accounting Firm
We consent to the use in this Registration Statement on Form S-1 of Angion Biomedica Corp. of our report dated May 13, 2020, except for the effect of the one-for-1.55583 stock split described in Note 16, as to which the date is February 1, 2021, relating to the consolidated financial statements of Angion Biomedica Corp. (which report expresses an unqualified opinion and includes explanatory paragraphs regarding a going concern emphasis and the adoption of ASC Topic 842 in 2019), and to the reference to our firm under the heading “Experts” in the Prospectus, which is part of this Registration Statement.
/s/ Moss Adams LLP
Seattle, Washington
February 1, 2021